Reference billing codes listed (does not imply coverage)

Included procedure and HCPCS codes are provided for reference only; listing does not imply coverage or guarantee payment. Codes shown in the policy include CPT 0232T (PRP injection), HCPCS G0460 and G0465 (autologous PRP for chronic wounds), M0076 (prolotherapy), and P9020 (PRP, each unit).

• 0232T — Injection(s), platelet rich plasma, any site, including image guidance, harvesting and preparation when performed.
• G0460 — Autologous platelet rich plasma (PRP) or other blood-derived product for nondiabetic chronic wounds/ulcers (per treatment).
• G0465 — Autologous PRP for diabetic chronic wounds/ulcers using an FDA-cleared device (per treatment).
• M0076 — Prolotherapy.
• P9020 — Platelet rich plasma, each unit.

If seeking authorization for prolotherapy, submit diagnosis, prior conservative care, and injectate details

Prior authorization requests for prolotherapy should include clinical documentation of the diagnosis, prior conservative therapies attempted, and details of the planned injectate (for example, concentration and volume) and treatment target (intra‑articular, peri‑articular, or perineural).

• Document diagnosis (e.g., KOA with Kellgren‑Lawrence grade 2–3 where applicable).
• Provide evidence of prior conservative care tried and failed (exercise/physiotherapy, medications, injections as appropriate).
• Specify planned injectate type and protocol (e.g., dextrose concentration/volume, number and interval of injections, route).

No single PA requirement specified in these excerpts — confirm plan-specific rules

The policy excerpts do not state a formal, uniform prior authorization process or explicit mandatory PA forms for all prolotherapy/PRP requests; plan‑specific requirements should be confirmed.

• No explicit universal prior authorization rules are specified in the cited sections.
• Providers should check member-specific plan and state contractual requirements before submission.

No explicit payer prior‑authorization statement present in these excerpts

The evidence summarized shows heterogeneous PRP/prolotherapy preparations and mixed RCT results; however, the excerpts do not present explicit payer-wide prior authorization language in the policy text provided.

• Heterogeneity of preparations and mixed trial outcomes are documented but do not translate to an explicit PA mandate in the cited excerpts.
• Policy language elsewhere may define administrative steps; always verify the full policy text and plan-specific procedures.

When PA is requested for PRP, require indication, failed conservative therapy, and PRP protocol details

If prior authorization is required for PRP, include indication, documentation of failure of conservative therapy, and a detailed PRP protocol (preparation method, platelet/leukocyte content, number/interval of injections).

• State the clinical indication and relevant disease severity (e.g., mild–moderate KOA when applicable).
• Document failed conservative therapies (physical therapy, medications, prior injections) with dates.
• Provide PRP protocol: preparation method, platelet counts or leukocyte‑rich/poor status, volume, activation method, and injection schedule.

Require PA evidence of failed conservative therapy and clinical rationale when conservative care not documented

When conservative care is not documented, require prior authorization to include evidence that standard conservative therapies were attempted and failed and a rationale for PRP use given limited comparative evidence.

• Provide documentation of prior conservative management (e.g., PT, exercise, oral therapies, corticosteroid injection where appropriate) and dates.
• Explain the clinical rationale for PRP/prolotherapy in this patient and reference objective measures or prior outcome measures if available.

PA requirement not specified in these wound‑care excerpts — verify plan/contract terms

No clear, uniform prior authorization mandate is specified in the cited wound‑care and other sections; the document highlights uncertainty and variable protocols that may influence PA decisions at the plan level.

• Cited evidence sections note variability and lack of standardized protocols but do not specify an across‑the‑board PA requirement.
• Verify any PA rules with the member’s benefit plan and state contractual terms.

If PA requested, disclose device/product and PRP preparation details

If PA is required, include device or product identification and PRP preparation details because devices/agents used may be subject to FDA regulation and PRP methods are heterogeneous.

• Identify the PRP device or kit used and whether an FDA‑cleared device is used for the intended indication.
• Document PRP preparation details (platelet concentration, leukocyte content, centrifugation method) and intended use.

Confirm plan‑specific requirements; UHC may use third‑party tools (e.g., InterQual) and contractual terms govern

UnitedHealthcare may use third‑party decision tools (for example, InterQual) and state/contractual benefit terms to administer benefits; check member‑specific plan requirements prior to authorization submission.

• Confirm whether the member’s plan requires additional third‑party criteria or forms (e.g., InterQual).
• Confirm federal, state, or contractual coverage requirements that may govern the decision.

Consider step‑therapy: trial standard conservative therapies before prolotherapy/PRP

Consider requiring a trial of conventional conservative therapies (for example, exercise/physiotherapy, oral analgesics, or corticosteroid injection where appropriate) before authorizing prolotherapy or PRP, consistent with trial populations in the evidence base.

• Document failed trials of standard conservative care, including dates and objective response.
• Consider physical therapy/exercise programs and appropriate medical management as prerequisites before advanced injectables.

Clinical context: PRP/prolotherapy intended for patients refractory to first‑line treatments

PRP and prolotherapy are generally described in the evidence as options for patients refractory to first‑line treatments rather than first‑line therapy; requests should reflect that clinical context.

• Use PRP/prolotherapy primarily for patients who have not responded to conservative care.
• Include prior treatment history demonstrating refractory status in the clinical record.

Document prior failure of conservative therapies—trial populations commonly included refractory patients

Many trials enrolled patients who had failed prior conservative therapies (for example, physiotherapy or shock wave therapy); provide documentation of these prior treatments when requesting PRP/prolotherapy.

• List prior conservative therapies tried and the duration/response for each (e.g., physiotherapy, shock wave therapy).
• Reference study‑like selection criteria when applicable (e.g., refractory after ≥3 months of nonoperative care).

Require trials of standard conservative treatments before PRP in many cases

Guidance from reviews suggests requiring trials of standard conservative treatments (oral medications, physical therapy) and appropriate alternatives (e.g., corticosteroid injection where indicated) before considering PRP.

• Document duration and response to conservative therapies.
• If corticosteroid injections were used, include timing relative to proposed PRP/prolotherapy (many trials excluded recent steroid injections).

For wound indications, document exhaustion of standard wound care before PRP

Consider requiring exhaustion of standard wound care measures (e.g., debridement, off‑loading for diabetic foot ulcers) before PRP for wound indications, consistent with evidence that PRP benefit is primarily shown as an adjunct to standard wound care in DFUs.

• Document prior standard wound care interventions, wound measurements, duration, and response.
• For DFUs, include off‑loading measures and prior local wound therapies applied.

Coding list is for reference only—presence in list does not indicate coverage

List of procedure and diagnosis codes is provided for reference; inclusion of codes in the policy does not imply coverage or guarantee payment—refer to the policy statement that listing does not imply coverage.

• Listing of codes is for reference only and may not be all‑inclusive.
• Benefit coverage is determined by federal, state, or contractual requirements; inclusion does not guarantee reimbursement.

Include diagnosis, failed conservative therapy, treatment route, and injectate details in documentation

When submitting documentation for authorization or review, include diagnosis (for example, KOA with Kellgren‑Lawrence grade when applicable), documentation of failed conservative therapy, treatment approach (intra‑articular vs peri‑articular), and injectate details (concentration, volume, schedule).

• Diagnosis with supporting imaging/grades where relevant (e.g., K‑L grade 2–3 for KOA).
• Prior conservative care attempts and dates.
• Planned treatment technique and injectate specifics (concentration/volume and number of injections).

Document baseline and follow‑up outcome measures (VAS, WOMAC, KOOS, DASH) used in trials

Clinical trial reports and reviews commonly include baseline and follow‑up outcome measures; document baseline scores and planned follow‑up outcome assessments (for example, VAS, WOMAC, KOOS, DASH) to support medical necessity evaluations.

• Record baseline patient‑reported outcome measures (VAS, WOMAC, KOOS, DASH/Q‑DASH, SPADI as applicable).
• Document planned follow‑up assessment timepoints and actual outcome results to mirror trial reporting.

Document PRP composition and preparation method (platelet counts, leukocyte content)

PRP preparation is heterogeneous across studies and is frequently underreported; when documented, include PRP composition (platelet counts, leukocyte content), preparation method, and number/frequency of injections.

• Report platelet concentration and whether PRP is leukocyte‑rich or leukocyte‑poor.
• Document centrifugation/preparation method, activation method if used, and number/interval of injections.

High denial risk: prolotherapy and PRP are considered unproven and not medically necessary

Requests for prolotherapy or PRP are subject to denial because these services are considered unproven and not medically necessary for any condition per the policy; ensure documentation addresses evidence gaps and selection criteria used in trials.

• Policy states prolotherapy and PRP are unproven and not medically necessary for any condition or indication.
• Provide robust, condition‑specific justification and documentation of prior therapies if seeking coverage consideration despite policy stance.

Denial risk increases when evidence shows methodological limitations (small, short, uncontrolled studies)

Methodological limitations commonly cited (small samples, lack of controls, short follow‑up, inconsistent objective outcomes) increase the likelihood of denial if submitted evidence replicates these limitations.

• Document objective measures and longer follow‑up where available to mitigate concerns about small, short trials.
• Address any study‑like limitations in the clinical rationale (e.g., use standardized PRP reporting and validated outcome instruments).

Denial risk: heterogenous PRP methods and limited long‑term/comparative data may lead to denial

Evidence limitations such as heterogeneity of PRP preparation, lack of long‑term follow‑up, and insufficient comparative data are specifically cited as reasons that may lead to medical necessity denial for routine PRP use.

• Provide long‑term outcome data and standardized PRP protocol details when available.
• Comparative evidence demonstrating superiority over standard treatments helps address these limitations.

Requests may be denied if evidence does not show superiority or sustained benefit of PRP

Routine PRP requests may be denied if submitted evidence does not demonstrate superiority or clear long‑term benefit over comparator treatments; include objective comparative data if available.

• Include comparative evidence showing clinical benefit beyond placebo, HA, or corticosteroid where available.
• If relying on evidence from trials, match patient selection and protocol details to those trials showing benefit.

Verify and follow federal, state, or contractual benefit plan requirements; they govern coverage

Coverage decisions must follow applicable federal, state, or contractual benefit plan requirements; this policy is informational and plan‑specific contractual terms govern if there is a conflict.

• Verify the member’s federal, state, or contractual benefit plan terms prior to undertaking treatment or PA submission.
• This Medical Policy supplements but does not supersede plan‑specific contractual requirements.